SureTrader SureTrader
Home > Boards > US OTC > Oil/Gas/Natural Energy Production >

Spotlight Innovation Inc. (STLT)

STLT RSS Feed
Add STLT Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Ecomike
Search This Board:
Last Post: 12/8/2016 7:40:55 PM - Followers: 28 - Board type: Free - Posts Today: 0
 



Spotlight Innovation Inc. (OTCQB: STLT) specializes in identifying, acquiring and incubating companies
which have unique intellectual property (IP) in the medical sector.
The Company utilizes relationships with the nation’s leading academic and institutional IP developers to
locate promising IP technologies with potential for market share capture.
With their support, development, resources and strategic planning expertise, Spotlight Innovation believes
they can develop IP that will have a positive effect on healthcare.
They intend to partner with proven sector leaders on commercialization once technologies are fully developed.

http://www.otcmarkets.com/stock/STLT/profile
 
Verified Company Profile3/29/2016
Contact Info
  • 6750 Western Parkway
    Suite 200-226
    West Des Moines, IA 50266
 
TLT Security Details
Share Structure
  Market Value1 $9,355,615 a/o Aug 29, 2016
  Authorized Shares 4,000,000,000 a/o Nov 04, 2014
  Outstanding Shares 15,856,974 a/o Aug 02, 2016
  -Restricted Not Available
  -Unrestricted Not Available
  Held at DTC Not Available
  Float 2,342,931 a/o Aug 02, 2016
  Par Value 0.001
Transfer Agent(s)
VStock Transfer LLC
Shareholders
Shareholders of Record 77 a/o Aug 02, 2016
Security Notes
  • Capital Change=shs increased by 14 for 1 split. Payable upon surrender. Pay date=08/19/2008.
    Capital Change=Stk. Div.=50% Ex-date=04/15/2009. Rec date=03/26/2009. Pay date=04/14/2009.
    Capital Change=shs decreased by 1 for 500 split. Ex-date=12/19/2013.










ZACKs Analyst report issued August 2015 http://share.myflare.com/MqVG9g

http://www.spotlightinnovation.com/download-whitepaper/

Website: http://www.spotlightinnovation.com

LinkedIn Company Page: http://www.linkedin.com/company/spotlight-innovation

YouTube/Google+ Company: http://www.youtube.com/user/spotlightinnovation

Twitter: https://twitter.com/SpotlightInno

Facebook: https://www.facebook.com/SpotlightInnovation

SPOTLIGHT INNOVATION INC.

6750 Westown Pkwy, Suite 200-226
West Des Moines, IA 50266
Phone: 515-274-9087

Milestones:

2015

JANUARY 2015
Spotlight Innovation subsidiary 
Celtic Biotech Iowa granted Patent by the U.S. Patent and Trademark Office

JANUARY 2015
Spotlight Innovation signs 
Memorandum of Understanding (MOU) with Black Swan LLC

2014

OCTOBER 2014
Spotlight Innovation signs 
Letter of Intent to Acquire Memcine Pharmaceuticals

SEPTEMBER 2014
Spotlight Innovation 
retains Jerry Cirino as Special Advisor

SEPTEMBER 2014
Spotlight Innovation 
retains Barwicki Investor Relations

AUGUST 2014
Spotlight Innovation
 publishes White Paper “Midwest Universities are Cultivating IP Commercialization Success”

JULY 2014
Spotlight Innovation receives 
$250,000 Line of Credit from Denver Savings Bank

JUNE 2014
Spotlight Innovation
 hires Dr. Hostelley as CFO

JUNE 2014
Spotlight Innovation closes 
equity placement of more than $41M: released to Company under certain specified conditions

JUNE 2014
Share exchange agreement finalized between Celtic Biotech Iowa and Celtic Biotech LTD, completing Celtic Biotech LTD acquisition

APRIL 2014
Spotlight Innovation
 receives $752,325 Line of Credit from Denver Savings Bank, secured by Jared DeVries

MARCH 2014
Celtic Biotech Iowa, Inc., becomes wholly-owned subsidiary of Spotlight Innovation Inc.

2013

DECEMBER 2013
AEXP/Spotlight Innovation merger completed

 

March 10, 2015
Spotlight Innovation subsidiary Celtic Biotech Iowa licenses promising therapy for Chronic Kidney Disease

Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa, Inc., entered into an exclusive, world-wide (excluding China) license agreement to develop and market a patent-pending invention related to the treatment of acute and chronic nephropathy, Use of Cardiotoxin for the Treatment of Chronic Kidney Disease (CKD).
Read more…


January 15, 2015
Spotlight Innovation subsidiary Celtic Biotech Iowa granted Patent by the U.S. Patent and Trademark Office

Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa Inc. has been granted U.S. Patent entitled Crotoxin Administration for Cancer Treatment and Pain Relief.  The invention relates to Crotoxin compositions for intravenous administration and methods of use of Crotoxin for the treatment of pain and/or for the treatment of neurologic and neuromuscular disorders.
Read more…


January 6, 2015
Spotlight Innovation signs Memorandum of Understanding (MOU) with Black Swan LLC

Spotlight Innovation Inc. (OTCQB:STLT) announces that it has entered into a Memorandum of Understanding with Black Swan LLC. Under the agreement, Black Swan will assist with activities such as identifying applicable government grants and loans, affecting beneficial changes to the legislative environment, advancing emerging technologies, identifying business partners, and developing new markets, particularly in the government sector.
Read more…


December 16, 2014
Spotlight Innovation announces change of Transfer Agent

Spotlight Innovation Inc. (OTCQB:STLT) announces today that effective December 16, 2014, all communications related to shareholder transactions should be directed to VStock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598.
Read more…


December 4, 2014
Celtic Biotech Iowa requests reactivation and transfer of National Drug Code registration

Spotlight Innovation Inc. (OTCQB:STLT) announces that a request was submitted to the Center for Drug Evaluation and Research at the Food and Drug Administration to reactivate and transfer the Celtic Biotech (Ireland) National Drug Code (NDC) registration to Celtic Biotech Iowa Inc. in anticipation of the manufacture and commercialization of a proprietary transdermal delivery gel product.
Read more…


October 14, 2014
Spotlight Innovation signs Letter of Intent to Acquire Memcine Pharmaceuticals

Spotlight Innovation Inc. (OTCQB:STLT) announced that it has signed a Letter of Intent to acquire majority ownership in Memcine Pharmaceuticals Inc., located at the University of Iowa Research Park in Coralville, Iowa. Memcine Pharmaceuticals is developing its Immunoplex™ vaccine platform technology, which is designed to use the body’s own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response.
Read more…


October 1, 2014
Spotlight Innovation Retains Jerry Cirino as Special Advisor

Spotlight Innovation Inc. (OTCQB: STLT) has hired Jerry Cirino as a Special Advisor to provide business development expertise and to advise the Company on strategic opportunities and transactions.
Read more…


September 24, 2014
Spotlight Innovation Retains Barwicki Investor Relations to Provide Global Investor Relations Program

Spotlight Innovation, Inc. (OTCQB: STLT) announced that it has retained Barwicki Investor Relations, a New York-based investor relations firm, to expand the Company’s strategic investor relations program. Barwicki Investor Relations is providing financial community and media relations, and editorial, consulting and advisory services.
Read more…


August 27, 2014
Spotlight Innovation white paper focuses on evolution of efforts to transform University research into profitable business ventures

Spotlight Innovation, Inc. (OTCQB:STLT) today published a white paper reporting the progress and growth of the transfer and commercialization of university-generated research and intellectual property (IP).
Read more…


August 5, 2014
Spotlight Innovation signs second Letter of Credit with Denver Savings Bank

Spotlight Innovation, Inc. (OTCQB:STLT) has entered into a second Letter of Credit with Denver Savings Bank, located in Denver, Iowa, in the amount of $250,000.00, effective July 29, 2014.
Read more…


July 02, 2014
Spotlight Innovation, Inc., announces closing of financing

Spotlight Innovation, Inc., (OTCQB:STLT) is pleased to announce that it has closed an equity placement of more than $41,418,000 with nine accredited investors, through its equity advisor Catwalk Capital, LLC.
Read more…


June 26, 2014
Spotlight Innovation names Dr. David Hostelley Chief Financial Officer

Spotlight Innovation, Inc. (OTCQB:STLT) today announced that effective June 20, 2014, Dr. David Hostelley has been named Chief Financial Officer of the Company.
Read more…


June 17, 2014
Spotlight Innovation building relationships with Midwest businesses and people

Cristopher Grunewald, President and CEO of Spotlight Innovation said, “The Midwest is a hotbed of talent and innovation, and it has always been a pillar of our business plan to build relationships with people and institutions in the Midwest. We are pleased that we are making good on this commitment.”
Read more…


June 10, 2014
Spotlight Innovation subsidiary Celtic Biotech Iowa, Inc., completes merger with Celtic Biotech Ltd.

Spotlight Innovation, Inc. (OTCQB:STLT) today announced that effective June 4, 2014, Celtic Biotech Iowa, Inc. (a subsidiary of Spotlight Innovation, Inc.) has completed a share exchange agreement with biopharmaceutical company Celtic Biotech Ltd.
Read more…


December, 16, 2013
Spotlight Innovation’s name change, symbol change and reverse split approved by FINRA

Spotlight Innovation, Inc. (“the Company”) (OTCQB:STLT) is pleased to announce that effective December 17, 2013 the Financial Industry Regulatory Authority (“FINRA”) has approved the name change of the company from American Exploration Corp. to Spotlight Innovation, Inc., change of stock symbol to “STLT”, and a 1-500 reverse split of our common stock.
Read more…


December 12, 2013
Spotlight Innovation, Inc. Announces Name Change and Closing of Merger

Spotlight Innovation, Inc. (formerly American Exploration Corporation, AEXP:OTCQB), announced today the completion of a merger with Spotlight Innovation, LLC.
Read more…


Spotlight Innovation is committed to developing quality-of-life-enhancing biotechnologies that have the potential to positively impact the health, well-being and longevity of an enormous number of lives. We are building a portfolio of healthcare/life sciences subsidiary companies, each having the potential to further our commitment.

Celtic Biotech Iowa Inc.

Celtic Biotech, Inc.

Celtic Biotech Iowa Inc., is developing novel therapeutic products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients.

Celtic Biotech Iowa Inc. is a subsidiary of Spotlight Innovation Inc.

Read the press release here.

Additional information about Celtic Biotech here.

Celtic Biotech Iowa Inc.

  

Management

Cristopher Grunewald, CEO

Mr. Grunewald is a financial executive and entrepreneur with background in the healthcare and biotechnology sectors, private equity and investment banking. He has been involved in all stages of the commercialization of healthcare IP developed by premiere research and development institutions.

Dr. David Hostelley, CFO

Dr. Hostelley has twenty years as a consultant in the health field, and has served as CEO, CFO and board member of several publicly traded companies. Dr. Hostelley is a CPA (inactive) licensed by the state of Ohio. He earned his Ph.D. in management while a lecturer in the MBA Program of Baldwin-Wallace College, and has lectured in Accounting and Management for Walsh University, North Canton, Ohio.

Jeffrey Stein, Esq., Securities Counsel

Mr. Stein serves as securities counsel for Spotlight Innovation. He has over fifteen years of experience providing high quality, personalized attention to public companies, including more than thirty reverse mergers, IPOs and APOs.

Rene Erickson, Corporate Communications

Mr. Erickson has three decades of corporate communications experience across diverse industries including healthcare, information technology, aviation and academia.

Mike Reysack, Investor Relations

Mr. Reysack leads Investor Relations for Spotlight Innovation. He has extensive experience cultivating and managing relationships with financial stakeholders, including fifteen years as an Investor Relations consultant and business strategist for venture and early stage companies, providing effective communications between companies and the financial community.

Special Advisor

Jerry Cirino

Mr. Cirino is a healthcare technology executive with extensive background in medical devices, distribution and healthcare information in private equity and public environments. His experience includes management of complex growth and transition environments including M&A, integrations and global operations, and he is a proven consultant in transaction evaluation, due diligence and strategic planning.

Partner Firms

Auditor

GBH CPAs, PC, Houston, TX

Transfer Agent

VStock Transfer, LLC, Woodmere, NY

Law Firms

Davis Brown Law Firm, Des Moines, IA
JMS Law Group, New York, NY
Eilers Law Group, Miami, FL
Whitfield & Eddy, P.L.C., Des Moines, IA




 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
STLT
Current Price
Volume:
Bid Ask Day's Range
SureTrader
News News Alert: Amended Statement of Changes in Beneficial Ownership (4/a) 12/08/2016 02:21:27 PM
PostSubject
#1448  Sticky Note The 8-K filled today by STLT explains this Ecomike 08/30/16 02:59:59 PM
#1491   STLT Detailed Quote mick 12/08/16 07:40:55 PM
#1490   Spotlight Innovation (STLT) mick 12/08/16 07:40:49 PM
#1489   Stock is under a Cease Trade Order in junkHustler 12/08/16 08:13:14 AM
#1487   NEWS subslover 12/06/16 09:44:34 AM
#1486   Well I totally disagree. Ecomike 11/20/16 10:38:08 PM
#1485   This is no 25-bagger from this level, you Murph32 11/19/16 10:26:57 AM
#1484   In 2009 it was an oil and gas Ecomike 11/10/16 09:59:30 PM
#1483   Holy Bio-Tech News that is a beautiful piece subslover 11/10/16 09:28:35 PM
#1482   I have a gut feeling the news on Ecomike 11/10/16 09:12:53 PM
#1481   You need to sign up on the STLT Ecomike 11/10/16 09:11:36 PM
#1480   Spotlight Innovation (STLT) mick 11/10/16 11:38:38 AM
#1479   Wow this is the first hearing about this. subslover 11/09/16 11:12:49 PM
#1478   What an interesting release by the company today. Ecomike 11/09/16 07:45:30 PM
#1477   That is an excellent point you make about subslover 11/08/16 10:10:29 PM
#1476   Folks should note the tiny float on this Ecomike 11/08/16 03:44:25 PM
#1475   My pleasure Ecomike,STLT has lots of promise for subslover 11/08/16 11:48:59 AM
#1474   Interesting, thanks for sharing. Ecomike 11/07/16 09:09:00 PM
#1473   Major connection here to MVM Life Sciences through subslover 11/07/16 11:44:42 AM
#1472   Thanks I had no time to look, Ihub Ecomike 11/04/16 08:11:45 PM
#1471   It obviously hit the waves if you just LarryAshy 11/04/16 05:14:05 PM
#1470   Not surer this has even hit the wire Ecomike 11/04/16 01:31:50 PM
#1469   Holy Crapola, this Bio-tech just squealed loud and Ecomike 11/04/16 11:57:09 AM
#1468   Spotlight Innovation (STLT) mick 10/29/16 06:41:23 PM
#1467   Spotlight Innovation (STLT) mick 10/16/16 11:24:09 PM
#1466   Spotlight Innovation (STLT) mick 10/01/16 01:25:27 PM
#1465   Spotlight Innovation (STLT) mick 09/18/16 03:27:14 PM
#1464   Annual Report (10-k) "Edgar (US Regulatory)" - 8/31/2016 mick 09/05/16 11:13:49 AM
#1463   Spotlight Innovation (STLT) mick 09/05/16 11:12:59 AM
#1462   good morning, good read mick 08/31/16 12:46:37 PM
#1461   Holy crapola, $STLT just filed the late 10-K Ecomike 08/31/16 12:20:16 PM
#1460   This company which is registred in the Oil FNDPennyStocks 08/31/16 09:22:21 AM
#1459   foundings always dare/////\\\\\ Spotlight Innovation Inc. (STLT)' mick 08/30/16 07:47:57 PM
#1458   Wasn't this company an oil and gas company jd19 08/30/16 07:41:01 PM
#1457   And they are under a current Cease Trade junkHustler 08/30/16 03:40:14 PM
#1456   Econ this company has NO real money! snakess 08/30/16 03:37:49 PM
#1455   We had a huge STLT rally today on Ecomike 08/30/16 03:36:20 PM
#1454   Be interesting to see what the short volume Ecomike 08/30/16 03:33:41 PM
#1453   STLT was a stable $2/share stock in 2014. Ecomike 08/30/16 03:30:54 PM
#1452   All STLT BIO-Technology comes from Government funded research Ecomike 08/30/16 03:27:43 PM
#1451   STLT technologies: Ecomike 08/30/16 03:26:06 PM
#1450   Biotech companies STLT has already bought: Ecomike 08/30/16 03:24:13 PM
#1449   News on STLT this year is here: Ecomike 08/30/16 03:10:09 PM
#1448   The 8-K filled today by STLT explains this Ecomike 08/30/16 02:59:59 PM
#1447   15 million shares common for a real biotech, Ecomike 08/30/16 02:53:26 PM
#1445   My break even on this stock is still Ecomike 08/30/16 02:31:11 PM
#1444   What gives you that idea? Has there been Ecomike 08/30/16 02:19:42 PM
#1443   INTERESTING COMPANY, 'Spotlight Innovation Inc. (STLT)' mick 08/30/16 01:49:37 PM
#1442   further review snakess 08/30/16 01:26:24 PM
#1441   hard to believe the excitement over this announcement. snakess 08/30/16 12:47:03 PM
#1440   Watching them $Pistol Pete$ 08/30/16 12:36:33 PM
PostSubject